Skip to content
Sunday, November 22, 2026
Media Remarks

Remarkable stories, clearly told.

Subscribe

Health

One-Time CRISPR Therapy Cuts Bad Cholesterol by 52 Percent

A single infusion of the experimental CRISPR therapy CTX310 cut bad cholesterol by 52.5 percent after a year in a small Cleveland Clinic trial of 15 patients.

Share WhatsApp Facebook X LinkedIn Email
Media Remarks image

One-Time CRISPR Therapy Cuts Bad Cholesterol by 52 Percent

A single infusion of an experimental gene editing therapy cut bad cholesterol by more than half for a full year in a small first human trial, and according to reports the result points to a future in which one treatment could replace daily pills for some patients. The therapy, called CTX310, uses CRISPR gene editing to switch off a gene in the liver, and the findings were published in the New England Journal of Medicine.

A Small Trial With a Striking Result

The Cleveland Clinic trial followed 15 patients with lipid disorders that had not responded to conventional drugs. Each received one infusion of CTX310 at doses from 0.1 to 0.8 milligrams per kilogram of body weight, after treatment with corticosteroids and antihistamines. After 12 months, patients on the highest dose saw bad cholesterol fall 52.5 percent from its starting level, while triglycerides fell 47.8 percent, and both reductions held across all doses through the year.

CTX310 carries the CRISPR editing machinery into the liver, where it switches off a gene called ANGPTL3, which helps control the fats circulating in the blood. The idea is to mimic a naturally occurring genetic variant that lowers cholesterol by reducing a liver protein. Lead author Dr Luke Laffin said the durability of the effect was impressive, and that it was encouraging that no serious safety events related to the therapy appeared during the year of follow up.

Early Days, With Larger Trials Still to Come

The treatment remains experimental, and the trial was small, so its long term safety and effectiveness still need confirmation in a much larger group of patients. One participant died 179 days after treatment, although researchers concluded that the death was unrelated to CTX310. The trial is funded by CRISPR Therapeutics, the company developing the treatment. A further phase of the trial is now under way, and participants will be monitored for another 15 years.

The results were presented at the 2026 European Society of Cardiology annual meeting and published at the same time in the medical journal. For people whose cholesterol stays high despite standard drugs, a one time treatment that lasts for years would be a major change, but doctors stress that the evidence so far comes from only 15 people, and that larger studies must confirm both the benefit and the safety before the therapy can reach patients.

Related Reading

Recent articles by Media Remarks Health & Science Desk

More from Health